Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Brexit
Waiting until the grace period expires before making a product application under the EU MDR or IVDR is a gambit that could easily misfire, TEAM-NB warns.
The end of the UK’s Brexit transition was the beginning of its new relationship as a “third country” with the EU.
There can be no such thing as a COVID dividend, but the renewed digital push and momentum for health system change perhaps come closest.
COVID-19 has forced a rethink in how care should be delivered. Healthcomms Consulting partner Dan Jones says it is an opportunity that must not be squandered.
Not only might each day feel like Groundhog Day now – with COVID-19 limiting everyone’s activities. But early 2021 puts the EU medtech sector in a similar place to early 2020. So what has changed?
Government and industry in the UK are determined to make the best of the Brexit free trade deal, but German medtechs are eager for trade flow practicalities to be prioritized.
Preparations for Brexit and the UK’s new medtech regulatory system kept the MHRA busy over the holiday period and into the new year.
Four out of 10 of Medtech Insight's top EU stories were dominated by news related to the implications for medtech of the UK’s final break from the EU on 31 December. But no one should ignore the pressure that implementation of the new EU medtech regulations is causing.
“No deal” is finally off the table for the UK trade in goods, after an 11th hour deal was agreed with the EU. But for UK medtech trade and regulation, the decision effectively means a “hard Brexit.”
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.